Synairgen (SNG) Competitors GBX 2 -0.18 (-8.26%) As of 02/21/2025 11:55 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlines SNG vs. ORPH, REDX, ETX, TRX, FUM, SBTX, COS, C4XD, DDDD, and POLBShould you be buying Synairgen stock or one of its competitors? The main competitors of Synairgen include Open Orphan (ORPH), Redx Pharma (REDX), e-therapeutics (ETX), Tissue Regenix Group (TRX), Futura Medical (FUM), SkinBioTherapeutics (SBTX), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), and Poolbeg Pharma (POLB). These companies are all part of the "biotechnology" industry. Synairgen vs. Open Orphan Redx Pharma e-therapeutics Tissue Regenix Group Futura Medical SkinBioTherapeutics Collagen Solutions plc (COS.L) C4X Discovery 4D pharma Poolbeg Pharma Synairgen (LON:SNG) and Open Orphan (LON:ORPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability, community ranking and media sentiment. Do institutionals and insiders hold more shares of SNG or ORPH? 30.7% of Synairgen shares are owned by institutional investors. 3.2% of Synairgen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community prefer SNG or ORPH? Synairgen received 153 more outperform votes than Open Orphan when rated by MarketBeat users. Likewise, 56.46% of users gave Synairgen an outperform vote while only 0.00% of users gave Open Orphan an outperform vote. CompanyUnderperformOutperformSynairgenOutperform Votes15356.46% Underperform Votes11843.54% Open OrphanOutperform VotesNo VotesUnderperform Votes2100.00% Does the media favor SNG or ORPH? In the previous week, Open Orphan had 1 more articles in the media than Synairgen. MarketBeat recorded 1 mentions for Open Orphan and 0 mentions for Synairgen. Open Orphan's average media sentiment score of 1.32 beat Synairgen's score of 0.00 indicating that Open Orphan is being referred to more favorably in the news media. Company Overall Sentiment Synairgen Neutral Open Orphan Positive Is SNG or ORPH more profitable? Open Orphan's return on equity of 0.00% beat Synairgen's return on equity.Company Net Margins Return on Equity Return on Assets SynairgenN/A -29.40% -30.58% Open Orphan N/A N/A N/A Which has preferable earnings & valuation, SNG or ORPH? Open Orphan has higher revenue and earnings than Synairgen. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynairgenN/AN/A-£15.86M-£1.66-1.20Open Orphan£34.71M0.00N/AN/AN/A SummarySynairgen and Open Orphan tied by winning 5 of the 10 factors compared between the two stocks. Get Synairgen News Delivered to You Automatically Sign up to receive the latest news and ratings for SNG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNG vs. The Competition Export to ExcelMetricSynairgenBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£19.55M£118.03M£5.84B£2.64BDividend Yield1.53%3.69%4.75%4.98%P/E Ratio-1.203.2026.38162.45Price / SalesN/A4,826.69435.33313,812.36Price / Cash1.9013.0138.0128.15Price / Book0.4247.077.645.16Net Income-£15.86M-£87.82M£3.19B£5.75B7 Day Performance-5.21%0.39%-2.12%-1.02%1 Month Performance8.70%3.65%-0.44%-0.86%1 Year Performance-57.08%99.16%16.30%39.56% Synairgen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNGSynairgenN/AGBX 2-8.3%N/A-59.4%£19.55MN/A-1.2034Gap DownORPHOpen OrphanN/AN/AN/AN/A£67.09M£34.71M-25.30179Positive NewsREDXRedx PharmaN/AN/AN/AN/A£58.35M£4.20M-150.00101News CoverageGap UpHigh Trading VolumeETXe-therapeuticsN/AN/AN/AN/A£52.59M£295,000.00-450.0035Positive NewsHigh Trading VolumeTRXTissue Regenix GroupN/AGBX 52-1.0%N/A-31.6%£46.88M£31.98M-53.68120FUMFutura MedicalN/AGBX 14.80+5.7%N/A-68.4%£46.13M£8.68M-12.2112Negative NewsSBTXSkinBioTherapeuticsN/AGBX 20.13+0.6%N/A+96.2%£45.97M£1.56M-12.3811High Trading VolumeCOSCollagen Solutions plc (COS.L)N/AN/AN/AN/A£30.99M£4.01M-8.283,350C4XDC4X DiscoveryN/AN/AN/AN/A£30.27M£24.68M300.0049High Trading VolumeDDDD4D pharmaN/AN/AN/AN/A£30.05M£718,000.00-1.08106POLBPoolbeg PharmaN/AGBX 4.97+1.4%N/A-64.1%£25.54MN/A-0.0112News CoverageGap Down Related Companies and Tools Related Companies Open Orphan Competitors Redx Pharma Competitors e-therapeutics Competitors Tissue Regenix Group Competitors Futura Medical Competitors SkinBioTherapeutics Competitors Collagen Solutions plc (COS.L) Competitors C4X Discovery Competitors 4D pharma Competitors Poolbeg Pharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:SNG) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synairgen plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Synairgen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
